To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Hepatotoxicity associated… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing

Journal article
Authors Einar Björnsson
Elin I. Jacobsen
Evangelos Kalaitzakis
Published in Journal of Hepatology
Volume 56
Pages 374-380
ISSN 01688278
Publication year 2012
Published at Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Pages 374-380
Language en
Keywords Drug-induced liver injury, Hepatoxicity, Statins
Subject categories Internal medicine


Background & Aims: Limited data exist on drug-induced liver injury (DILI) associated with statins. Methods: Reports on adverse reactions suspected to be due to statins received by the Swedish Adverse Drug Reactions Advisory Committe 1988-2010 were analyzed. Only cases with >5 × upper limit of normal (ULN) in aminotransferases and/or alkaline phosphatase >2 × ULN were included. Results: The most common types of ADRs suspected were DILI in 124/217 (57%) cases. A total of 73/124 (59%) cases had at least possible relationship, median age 64 years (57-73), 55% males, whereas 25/124 cases (20%) were excluded due to mild elevations of liver tests and 26 due to unlikely relationship and/or lack of data. A statin-related DILI episode was reported in 1.2/100,000 users. Atorvastatin was implicated in 30/73 (41%) cases, simvastatin in 28 (38%), fluvastatin (15%), and others. Two patients died of acute liver failure, one underwent liver transplantation and 25 (34%) had jaundice. Three patients were rechallenged with the same statin producing similar patterns of liver injury. The median duration of therapy was 90 days (30-120), 120 (39-248) for atorvastatin, and 75 (30-150) for simvastatin (NS). Cholestatic/mixed injury was more common with atorvastatin, 17/30 (56%) than with simvastatin, 7/28 (24%) (p = 0.018). Conclusions: Idiosyncratic liver injury associated with statins is rare but can be severe. After recovery, a similar pattern of liver injury can be reproduced on re-exposure. Most patients experience liver injury 3-4 months after start of therapy. Atorvastatin is mostly associated with cholestatic liver injury whereas hepatocellular injury is more common with simvastatin. © 2011 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?